Ryan Reber, DO
Pulmonary Disease · Wynnewood, PANPI 1134352255
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,379 of the $93,765 with a category attached, or 62.3%. Mylan Specialty L.p. accounts for 83.7% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $29,782 and has fallen 77.0% since, to $6,862 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $157.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$79K
- Viatris Specialty LLC$5K
- AstraZeneca$3K
- GSK$1K
- Insmed, Inc.$1K
- Johnson & Johnson$898
- plus $4K from 34 others
What the payments were for
- Consulting fees$19,67921%
- Speaking & faculty fees$58,37962%
- Travel & lodging$3,7284%
- Food & beverage$11,89213%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 171 | $78,504 |
| Viatris Specialty LLC | 15 | $5,007 |
| AstraZeneca(2 entities) | 121 | $2,626 |
| GSK | 82 | $1,384 |
| Insmed, Inc. | 24 | $1,255 |
| Johnson & Johnson | 31 | $898 |
| Boehringer Ingelheim | 28 | $750 |
| Mylan Inc. | 1 | $663 |
| Philips North America LLC | 25 | $462 |
| Regeneron Healthcare Solutions, Inc. | 11 | $324 |
| Sanofi | 11 | $259 |
| Genentech USA, Inc. | 8 | $166 |
| Harmony Biosciences LLC | 5 | $120 |
| Amgen | 5 | $117 |
| Electromed, Inc. | 5 | $110 |
| Grifols USA, LLC | 5 | $109 |
| Inogen, Inc. | 5 | $98 |
| AbbVie | 4 | $85 |
| Verona Pharma, Inc. | 3 | $70 |
| ANI Pharmaceuticals, Inc. | 2 | $67 |
| Baxter Healthcare | 2 | $67 |
| Novartis | 3 | $63 |
| United Therapeutics Corporation | 3 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 3 | $49 |
| Pfizer | 2 | $49 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Lilly USA, LLC | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Circassia Inc. | 2 | $30 |
| Pulmonx Corporation | 2 | $29 |
| Atricure, Inc. | 1 | $29 |
| CSL Behring | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Eisai Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Resmed Corp | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,765 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 23 | $298,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $173,907 |
| XolairOmalizumab | 34 | $81,987 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $48,197 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $40,200 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $35,951 |
| EliquisApixaban | 43 | $25,105 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $20,008 |
| Spiriva RespimatTiotropium Bromide | 16 | $13,173 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $10,385 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 54 | $9,560 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 72 | $8,382 |
| Arnuity ElliptaFluticasone Furoate | 31 | $7,648 |
| XareltoRivaroxaban | 12 | $6,700 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 220 | $5,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $750 | $332,12568 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,384 | $261,797397 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,626 | $58,58296 claims |
| PfizerEliquis | $49 | $25,10543 claims |
| Johnson & JohnsonXarelto | $898 | $6,70012 claims |
| Mylan Inc.Wixela Inhub | $663 | $2,67317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Wynnewood
- Thomas MeyerWynnewood$615K
- Jacqueline SutterWynnewood$189K
- Robert PromisloffWynnewood$50K
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.